indacaterol, inhaled (Rx)Brand and Other Names:Arcapta Neohaler


Dosing & Uses


Dosage Forms & Strengths

capsule, powder for inhalation

  • 75mcg/capsule


Long-acting beta2-agonist indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema

75 mcg inhaled orally qDay; not to exceed once daily

Limitations of use

  • Not indicated for acute deteriorations of COPD
  • Not indicated for asthma


For oral inhalation only

Do not swallow the capsules for inhalation; if swallowed, intended effects on the lungs will not be obtained

For use with Neohaler inhaler device only

Administer qDay at the same time of the day by the oral inhalation route only

If a dose is missed, the next dose should be taken as soon as it is remembered

Not to exceed once daily administration

Store capsule in the blister pack it comes in until immediately before use

Safety and efficacy not established

No dosage adjustment is required for geriatric patients, patients with mild-to-moderate hepatic impairment, or patients with renal impairment

Data are not available for severe hepatic impairment



Interaction Checker

indacaterol, inhaled and

No Results

     activity indicator 
    No Interactions Found
    Interactions Found


      Serious - Use Alternative

        Significant - Monitor Closely


            Sort by :  
             activity indicator 

            Adverse Effects


            Post-inhalation cough (24% compared with 7% on placebo)


            Cough (6.5%)

            Nasopharyngitis (5.3%)

            Headache (5.1%)

            Nausea (2.4%)

            Oropharyngeal pain (2.2%)

            Postmarketing Reports

            Hypersensitivity reactions

            Paradoxical bronchospasm

            Tachycardia/heart rate increase/palpitations






            Black Box Warnings

            Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death

            Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol

            This finding with salmeterol is considered a class effect of LABA, including indacaterol

            The safety and efficacy of indacaterol in patients with asthma have not been established

            Indacaterol is NOT indicated for the treatment of asthma



            All long-acting beta2-adrenergic agonists (LABAs) are contraindicated in patients with asthma without use of a long-term asthma control medication


            Do not initiate in acutely deteriorating COPD patients

            Do not use for relief of acute symptoms; prescribe concomitant short-acting beta2-agonists for acute exacerbations

            Do not exceed recommended daily dose; excessive doses may result in cardiovascular effects and may be fatal

            Life-threatening paradoxical bronchospasm can occur; discontinue use immediately

            Immediate hypersensitivity reactions reported; discontinue immediately and initiate alternate therapy

            Data from a large placebo-controlled study in asthma patients showed that long-acting beta2-adrenergic agonists may increase the risk of asthma-related death (see Black Box Warnings)

            Caution with CV disease, epilepsy, thyrotoxicosis, or sensitivity to sympathomimetics

            Contains trace levels of milk protein

            Tolerance to the effects of inhaled beta-agonists can occur with regularly-scheduled, chronic use

            Increased sympathomimetic effects may occur if coadministered with other adrenergic drugs

            May cause hypokalemia; this effect may be potentiated if coadministered with xanthine derivatives, corticosteroids, or diuretics

            ECG changes or hypokalemia that may result from non-potassium sparing diuretics (eg, thiazides or loop diuretics) can be acutely worsened by beta-agonists, especially with high doses; use caution

            Caution with coadministration of MOAIs, TCAs, and drugs that prolong QTc interval

            Beta blockers may antagonize the effect of indacaterol

            Strong dual inhibitors of CYP3A4 and P-gp (ie, ketoconazole, erythromycin, verapamil, ritonavir) may delay systemic clearance of indacaterol (AUC increased 1.9-fold); no dose adjustment is warranted with 75 mcg/day

            Beta2 agonists may increase serum glucose; use caution in patients with diabetes mellitus

            Use caution in patients with seizure disorders


            Pregnancy & Lactation

            Pregnancy Category: C

            Beta-agonists are known to inhibit uterine contractility

            Lactation: Unknown whether distributed in human breast milk; use caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.



            Mechanism of Action

            Long-acting beta2-adrenergic agonist; when inhaled, acts locally in the lung as a bronchodilator

            Stimulates intracellular adenyl cyclase, causing conversion of ATP to cyclic AMP; increased cyclic AMP levels cause relaxation of bronchial smooth muscle

            In vitro studies have shown that indacaterol has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors (selectivity profile is similar to formoterol)


            Bioavailability: 43-45% following inhalation (composite of pulmonary and intestinal absorption)

            Peak Plasma Time: 15 min


            Protein Bound: 95% (after IV administration)

            Vd: 2361-2557 L (after IV administration)


            Metabolized by UGT1A1, CYP3A4 (predominant for hydroxylation), CYP1A1, CYP2D6

            Low affinity for efflux pump P-gp

            In vitro investigations indicated that indacaterol has negligible potential to cause metabolic interactions with medications (by inhibition or induction of cytochrome P450 enzymes, or induction of UGT1A1)


            Half-life (terminal): 45.5-126 hr, multiphasic half-life

            Half-life (effective): 40-56 hr, calculated from accumulation after repeated dosing

            Renal clearance: 0.46-1.2 L/hr

            Total body clearance: 18.8-23.3 L/hr

            Excretion: feces (54% unchanged, 23% hydroxylated metabolites), urine (<2%)


            Pharmacokinetics were prospectively investigated in individuals with the UGT1A1 (TA)7/(TA)7 genotype (low UGT1A1 expression; also referred to as *28) and the (TA)6, (TA)6 genotype

            Steady-state AUC and Cmax were 1.2-fold higher in the [(TA)7, (TA)7] genotype, suggesting no relevant effect of UGT1A1 genotype of indacaterol exposure





            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient



            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient



            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.